Chemical subgroup
L01XL – Antineoplastische Zell- und Gentherapie
17Decisions
23Patient groups
Added benefit by patient group
- Considerable2
- Minor1
- Non-quantifiable9
- Not proven11
Decisions, newest first
- 2026-06-04BreyanziLisocabtagen maraleucelNot proven
- 2025-10-02BreyanziLisocabtagen maraleucelNot proven
- 2025-05-15CarvyktiCiltacabtagen autoleucelConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2024-12-19YescartaAxicabtagen-CiloleucelMinor
- 2024-09-19AbecmaIdecabtagen vicleucelNot proven
- 2024-02-15KymriahTisagenlecleucelNon-quantifiable
- 2024-02-15KymriahTisagenlecleucelNon-quantifiable
- 2023-12-21YescartaAxicabtagen-CiloleucelNot proven
- 2023-11-16BreyanziLisocabtagen maraleucelConsiderable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2023-10-05EbvalloTabelecleucelNon-quantifiable
- 2023-04-06BreyanziLisocabtagen maraleucelNot proven
- 2023-03-16TecartusBrexucabtagen autoleucelNon-quantifiable
- 2022-12-01KymriahTisagenlecleucelNon-quantifiable
- 2022-11-03YescartaAxicabtagen-CiloleucelNon-quantifiable: 2 of 2 patient groups
- 2022-06-16AbecmaIdecabtagen vicleucelNon-quantifiable
- 2021-08-05TecartusBrexucabtagen autoleucelNon-quantifiable
- 2016-12-15ImlygicTalimogen laherparepvecNot proven: 3 of 3 patient groups
Data status: 2026-10-29